Pfizer Gains Anti-Inflammatory Compound Development Rights Through Incyte Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the agreement for CCR2 antagonists, Incyte will maintain rights to multiple sclerosis and a second undisclosed indication.
You may also be interested in...
Phase II Diabetes Data Heighten Incyte’s Partnership Appeal
Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.
Phase II Diabetes Data Heighten Incyte’s Partnership Appeal
Novel compound that acts on cortisol gives DPP-4 inhibitors a run for their money.
Multiple Internal Champions Can Propel Complex Licensing Deals, Pfizer Exec Says
Incyte deal is a model for negotiations involving multiple therapeutic areas, Pfizer exec tells licensing meeting.